Shaji Kumar, MD, on Stem Cell Transplant and First-Line Multiple Myeloma Treatment With Bortezomib, Lenalidomide, and Dexamethasone

Posted: Friday, May 29, 2020

Shaji Kumar, MD, of the Mayo Clinic, discusses findings from the ENDURANCE trial and how transplant fits in the overall treatment plan for patients with newly diagnosed standard- or intermediate-risk multiple myeloma.